# Colchicine Protective Effect in Patients Undergoing Percutaneous Coronary Intervention (COLCHICINE-PROTECT)

Study · id `cardio:ct-nct05739929` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05739929](<https://clinicaltrials.gov/study/NCT05739929>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05739929

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT05739929. Randomized; quadruple masking; primary purpose treatment. Start 2023-03-01 (actual); primary completion 2024-08-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT05739929, source copy `cardio:ctgov-nct05739929-2023-03-22`, retrieved 2026-10-26)
- Started: 2023-03-01 (actual) (ClinicalTrials.gov record NCT05739929, source copy `cardio:ctgov-nct05739929-2023-03-22`, retrieved 2026-10-26)
- Primary completion: 2024-08-30 (anticipated) (ClinicalTrials.gov record NCT05739929, source copy `cardio:ctgov-nct05739929-2023-03-22`, retrieved 2026-10-26)
- Completion: 2024-08-30 (anticipated) (ClinicalTrials.gov record NCT05739929, source copy `cardio:ctgov-nct05739929-2023-03-22`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT05739929, source copy `cardio:ctgov-nct05739929-2023-03-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05739929-2023-03-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Colchicine Protective Effect in Patients Undergoing Percutaneous Coronary Intervention (COLCHICINE-PROTECT)
- Condition: Coronary Artery Disease
- Intervention (Drug): Colchicine 0.5 MG Oral Tablet
- Intervention (Drug): Placebo
- Lead sponsor: Helwan University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Colchicine (`cardio:colchicine`)
- Registry lists this organization as the lead sponsor: Helwan University (`cardio:org-helwan-university`)

## Provenance

Content hash: c0203912cbc4ff05c75bdda1fde560d176974b726efb6e7f6debd446e1d072f5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
